(Q44872919)

English

Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD.

scientific article published on 16 December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

1 reference

based on heuristic

inferred from title

mantle cell lymphoma

1 reference

based on heuristic

inferred from title

author name string

Anthony R Mato

1

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Jakub Svoboda

2

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Tatyana Feldman

3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Tania Zielonka

4

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Harry Agress

5

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

David Panush

6

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Mitchell Miller

7

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Patrick Toth

8

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Paul M Lizotte

9

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Sunita Nasta

10

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Stuart Goldberg

11

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Emeline Chong

12

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Steven Schuster

13

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Andrew L Pecora

14

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Andre Goy

15

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

language of work or name

0 references

publication date

16 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

118

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

3565-3570

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

How I treat mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

[18F]fluorodeoxyglucose positron emission tomography in the management of lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

Positron emission tomography in mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

[18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organiza

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

21 January 2018

Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

7 January 2021

based on heuristic

inferred from DOI database lookup

The mysteries of mantle cell lymphoma--do PET scans provide a clue?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26731

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.26731

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44872919&oldid=1521050145"